Recent from talks
1-Propyl-5-MeO-AMT
Knowledge base stats:
Talk channels stats:
Members stats:
1-Propyl-5-MeO-AMT
1-Propyl-5-MeO-AMT, also known as 1-propyl-5-methoxy-α-methyltryptamine, is a serotonin receptor modulator of the tryptamine, α-alkyltryptamine, and 5-methoxytryptamine families. It is the 1-propyl derivative of 5-methoxy-α-methyltryptamine (5-MeO-AMT).
Whereas most tryptamines are highly non-selective in terms of binding to serotonin receptors, 1-propyl-5-MeO-AMT shows selectivity for the serotonin 5-HT2A receptor. Its affinities (Ki) for serotonin receptors were 12 nM for the serotonin 5-HT2A receptor, 120 nM for the serotonin 5-HT2C receptor, 5,000 nM for the serotonin 5-HT1B receptor, 7,100 nM for the serotonin 5-HT1A receptor, and >10,000 nM for the serotonin 5-HT1D receptor, whereas other serotonin receptors were not reported. Its capacity and potency in activating the serotonin receptors was also not reported.
The drug was developed by Richard Glennon and colleagues and was first described in 1990. At the time, it was described as the most 5-HT2A receptor-selective tryptamine known to date.
Hub AI
1-Propyl-5-MeO-AMT AI simulator
(@1-Propyl-5-MeO-AMT_simulator)
1-Propyl-5-MeO-AMT
1-Propyl-5-MeO-AMT, also known as 1-propyl-5-methoxy-α-methyltryptamine, is a serotonin receptor modulator of the tryptamine, α-alkyltryptamine, and 5-methoxytryptamine families. It is the 1-propyl derivative of 5-methoxy-α-methyltryptamine (5-MeO-AMT).
Whereas most tryptamines are highly non-selective in terms of binding to serotonin receptors, 1-propyl-5-MeO-AMT shows selectivity for the serotonin 5-HT2A receptor. Its affinities (Ki) for serotonin receptors were 12 nM for the serotonin 5-HT2A receptor, 120 nM for the serotonin 5-HT2C receptor, 5,000 nM for the serotonin 5-HT1B receptor, 7,100 nM for the serotonin 5-HT1A receptor, and >10,000 nM for the serotonin 5-HT1D receptor, whereas other serotonin receptors were not reported. Its capacity and potency in activating the serotonin receptors was also not reported.
The drug was developed by Richard Glennon and colleagues and was first described in 1990. At the time, it was described as the most 5-HT2A receptor-selective tryptamine known to date.
Recent media